期刊文献+

再生障碍性贫血合并乙肝病毒感染:临床特征和病毒活化预防

Aplastic anemia combined with hepatitis B virus infection:Clinical features and prevention of virus activation
原文传递
导出
摘要 再生障碍性贫血(aplastic anemia,AA)是由于T淋巴细胞功能亢进攻击造血干/祖细胞而导致的造血功能衰竭症。胎肝在人胚第6周即开始造血,至第4~5个月达到高峰,并被骨髓造血逐渐替代,因此肝脏细胞与造血细胞存在一定交叉抗原,而临床上也常发现肝炎相关性AA,主要由血清学阴性的肝炎所致,基本发生在肝炎后肝功能恢复期,偶有报道是继发于甲、乙或丙型肝炎病毒感染后。
出处 《临床血液学杂志》 CAS 2017年第6期826-829,共4页 Journal of Clinical Hematology
关键词 再生障碍性贫血 乙型肝炎病毒 临床特征 病毒活化 预防 aplastic anemia hepatitis B virus clinical features virus activation prevention
  • 相关文献

参考文献7

二级参考文献71

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2夏伟良,谢海洋,沈岩,吴李鸣,张峰,郑树森.环孢素和他克莫司在体外对乙型肝炎病毒复制影响的对比研究[J].中华医学杂志,2006,86(2):111-115. 被引量:12
  • 3Young NS, Brown KE, Lu J, et al. Analysis of T cell repertoire in hepatitis-associated aplastic anemia. Blood,2004,103 ( 12 ) :4588-4593.
  • 4Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Threeyears of continuous entecavir therapy in treatment-nae chronichepatitis B patients: VIRAL suppression, viral resistance, andclinical safety. Am J Gastroenterol 2011; 106: 1264-1271 [PMID:21364549 DOI: 10.1038/ajg.2011.45].
  • 5Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM,Washington MK, Germanidis G, Flaherty JF, Schall RA, BornsteinJD, Kitrinos KM, Subramanian GM, McHutchison JG, HeathcoteEJ. Regression of cirrhosis during treatment with tenofovirdisoproxil fumarate for chronic hepatitis B: a 5-year open-labelfollow-up study. Lancet 2013; 381: 468-475 [PMID: 23234725DOI: 10.1016/S0140-6736(12)61425-1].
  • 6Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, SafadiR, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R,Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy resultsin the reversal of fibrosis/cirrhosis and continued histologicalimprovement in patients with chronic hepatitis B. Hepatology2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785].
  • 7Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW,Wong BC, Fung J, Yuen JC, Lai CL. Long-term lamivudine therapyreduces the risk of long-term complications of chronic hepatitis Binfection even in patients without advanced disease. Antivir Ther2007; 12: 1295-1303 [PMID: 18240869].
  • 8Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, IuHW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavirtreatment reduces hepatic events and deaths in chronic hepatitisB patients with liver cirrhosis. Hepatology 2013; 58: 1537-1547[PMID: 23389810 DOI: 10.1002/hep.26301].
  • 9Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, EggersBJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, ColonnoRJ. Long-term monitoring shows hepatitis B virus resistance toentecavir in nucleoside-nae patients is rare through 5 years oftherapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI:10.1002/hep.22841].
  • 10Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A,Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistanceto tenofovir disoproxil fumarate after 6 years of therapy in patientswith chronic hepatitis B. Hepatology 2014; 59: 434-442 [PMID:23939953 DOI: 10.1002/hep.26686].

共引文献862

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部